Red Queen Therapeutics

Executive Summary

Red Queen Therapeutics is a preclinical-stage biopharmaceutical company headquartered in San Diego, focused on developing novel small molecule therapeutics to combat infectious diseases, particularly antimicrobial-resistant (AMR) pathogens and emerging viruses. Founded in 2020, the company has raised $55 million to advance its pipeline, which leverages a unique strategy targeting pathogen-specific biological vulnerabilities to overcome resistance mechanisms. The company's approach addresses a critical global health need, as AMR infections are rising and novel antibiotics are scarce. While still in preclinical development, Red Queen's substantial funding and clear scientific focus position it as a potential player in the infectious disease space, though it faces high technical and regulatory risks inherent to early-stage drug development.

Upcoming Catalysts (preview)

• Q3 2026Lead candidate selection for lead program60% success
• Q1 2027Initiation of IND-enabling studies50% success
• Q4 2026Series B financing round70% success